πŸ‡ΊπŸ‡Έ FDA
Patent

US 11752214

Protein-antiviral compound conjugates

granted A61KA61K31/506A61K31/5383

Quick answer

US patent 11752214 (Protein-antiviral compound conjugates) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/506, A61K31/5383, A61K47/6801, A61K47/6803